GlaxoSmithKline has entered a major three-part transaction with Novartis involving its Consumer Healthcare, Vaccines, and Oncology businesses. The two companies will create a new Consumer Healthcare business, for which GSK will have majority control with an equity interest of 63.5%.   GSK will acquire Novartis’ global Vaccines business (excluding influenza vaccines) for an initial cash consideration of $5.25 billion and subsequent potential milestone payments of as much as $1.8 billion, as well ...